The specific objectives of the Administrative Core are: Oversee all SPORE activities, including Projects and Core support functions Ensure compliance with institutional, governmental, and NCI regulations Assume responsibility for communications and consultations with the NCI project officer and other NCIstaff to ensure timely preparation and submission of reports and publications Oversee the fiscal and budgetary activities of the SPORE Coordinate data control quality assurance issues in conjunction with the Internal Scientific AdvisoryCommittee and the Biostatistics and Data Management Core (Core C) Coordinate activities associated with clinical trials, e.g., designs, approval by regulatory bodies,implementation, and eligibility and assignment of patients to different studies Provide oversight and support for the Biostatistics and Data Management Core (Core C) and thePathology and Tissue Core (Core B) Coordinate meetings of the Executive Committee, the Internal and External Scientific AdvisoryCommittees, monthly investigator meetings, quarterly research meetings, lectures, and symposia Administer the Developmental Research Program and the Career Development Program Administer the activities of the Patient Advocates Ensure compliance with and improvement of policies for recruitment of women and minorities Coordinate with other Leukemia SPORE programs and investigators, and other organ-site SPOREprograms, to promote communications and integration, through sponsoring a yearly SPORE conference,and distribute materials, electronic communications and progress reports Organize seminars to bring to M. D. Anderson consultants and speakers; sponsor a yearly conference onTranslational Research in Leukemia Maintain a Leukemia SPORE websiteLay Description: The purpose of the Leukemia SPORE Administrative Core is to provide administrative,fiscal, and regulatory support for the Projects and Cores as well as maintain continuity of the overall activitiesof the grant program projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-06
Application #
7468681
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$91,921
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674

Showing the most recent 10 out of 487 publications